on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies to Participate in 26th Annual HC Wainwright Global Investment Conference
DBV Technologies, a biopharmaceutical company listed on Euronext and Nasdaq, announced its participation in the 26th Annual HC Wainwright Global Investment Conference. Daniel Tassé, Chief Executive Officer, will participate in a “Fireside Chat” on September 9, 2024 at 3:00 p.m. ET in New York City.
The presentation will be webcast live and available on the “Events” page of the company’s website. A replay will be available for 90 days following the event.
DBV Technologies develops treatments for food allergies and other immunological conditions. Its flagship product, the VIASKIN® patch, uses epicutaneous immunotherapy to desensitize patients to allergens.
Headquartered in Châtillon, France, with operations in North America, DBV Technologies is listed on Euronext and Nasdaq.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news